Evidence map›Paper›PMID 39766541›Full record

ArticleAntibiotics (Basel, Switzerland)2024

National Cohort of Compassionate Use of Meropenem-Vaborbactam: No Benefit over Meropenem for

Aurélien Dinh, Alexandre Bleibtreu, Clara Duran, Frédérique Bouchand, Alexie Bosch, Jullien Crozon-Clauzel, Mariam Roncato-Saberan, Morgan Matt, André Boibieux, Annlyse Fanton and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Resistance mechanisms and therapeutic strategies forTherapeutic advances in infectious disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Aurélien DinhInfectious Disease Unit, Raymond-Poincaré University Hospital, AP-HP Paris Saclay University, 92380 Garches, France.ORCID 0000-0002-5843-4819
Alexandre BleibtreuInfectious Disease Unit, La Pitié-Salpétrière University Hospital, AP-HP University of Paris, 75013 Paris, France.ORCID 0000-0001-5145-4174
Clara DuranInfectious Disease Unit, Raymond-Poincaré University Hospital, AP-HP Paris Saclay University, 92380 Garches, France.
Frédérique BouchandPharmacy, Raymond-Poincaré University Hospital, AP-HP Paris Saclay University, 92380 Garches, France.
Alexie BoschInfectious Disease, Chambery Hospital, 73000 Chambery, France.
Jullien Crozon-ClauzelSurgical Intensive Care Unit, University Hospital, 69000 Lyon, France.
Mariam Roncato-SaberanInfectious Disease Unit, 17000 La Rochelle, France.
Morgan MattInfectious Disease Unit, Private Hospital Bordeaux Nord Aquitaine, 33300 Bordeaux, France.
André BoibieuxInfectious Disease Unit, University Hospital, 69000 Lyon, France.
Annlyse FantonPulmonology Department, University Hospital, 21231 Dijon, France.
Heidi WilleInfectious Disease Department, Centre hospitalier de la Côte Basque, 64100 Bayonne, France.
Elise FiauxInfectious Disease Department, University Hospital, 76000 Rouen, France.
Benoît PilmisInfectious Disease Unit, Hopital Saint Joseph, 75014 Paris, France.
Marie LacosteInfectious Disease Department, Alpes Leman Hospital, 74130 Contamine Sur Arve, France.
Quentin Saint-GenisSurgical Intensive Care Unit, University Hospital, 86000 Poitiers, France.ORCID 0009-0000-6420-0480
Caroline ThumerellePediatric Pulmonology Department, University Hospital, University Lille, CHU Lille, 59000 Lille, France.
Patricia PaveseInfectious Disease Department, University Hospital, 38000 Grenoble, France.
Fanny VuottoInfectious Disease Department, University Hospital, 59000 Lille, France.
Eric SennevilleInfectious Disease Department, University Hospital, 59599 Tourcoing, France.ORCID 0000-0002-5720-8908
Anaïs PotronMicrobiology Laboratory, University Hospital, 25000 Besançon, France.
Stéphane CorvecMicrobiology Laboratory, CHU Nantes, University Nantes, INCIT U1302, 44000 Nantes, France.ORCID 0000-0003-3176-8111
David BoutoilleInfectious Disease Department, CIC 1413 INSERM, University Hospital, 44000 Nantes, France.
Katy JeannotMicrobiology Laboratory, University Hospital, 25000 Besançon, France.ORCID 0000-0002-4634-8550
Laurent DortetMicrobiology Laboratory, Bicêtre University Hospital, AP-HP Paris Saclay University, 94270 Le Kremlin-Bicêtre, France.ORCID 0000-0001-6596-7384
On Behalf Of The Meropenem-Vaborbactam French Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMeropenem-vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an effective inhibitor of KPC enzymes in vitro. This study aimed to describe the initial uses and efficacy of MEM-VAB for compassionate treatment during the first 21 months following its early access in France.

methodA national multicenter retrospective study was conducted, including all patients who received at least one dose of MEM-VAB between 20 July 2020, and 5 April 2022. Clinical characteristics and outcomes were collected using a standardized questionnaire. The minimum inhibitory concentration (MIC) of antimicrobials, and complete genome sequencing of bacteria were performed when bacterial isolates were available.

resultsUltimately, 21 patients from 15 French hospitals were included in the study. The main indication for MEM-VAB treatment was respiratory tract infections (

conclusionsMEM-VAB seems effective as a salvage treatment in compassionate use, but vaborbactam was shown to lack benefits compared to meropenem in treating

Indexed as

bacterial resistancecarbapenemmeropenem–vaborbactamPseudomonas aeruginosarespiratory tract infection

Identifiers

PMID39766541
PMCPMC11672642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.